hsp90 β选择性抑制剂抗三阴性乳腺癌(TNBC)的蛋白质组学分析以获得机制见解。

IF 5.5 2区 生物学 Q1 BIOCHEMICAL RESEARCH METHODS
Molecular & Cellular Proteomics Pub Date : 2025-09-01 Epub Date: 2025-07-24 DOI:10.1016/j.mcpro.2025.101043
Tyelor S Reynolds, Daniel D Hu, Simon D Weaver, Emma C Ronck, Sanket J Mishra, Matthew M Champion, Brian S J Blagg
{"title":"hsp90 β选择性抑制剂抗三阴性乳腺癌(TNBC)的蛋白质组学分析以获得机制见解。","authors":"Tyelor S Reynolds, Daniel D Hu, Simon D Weaver, Emma C Ronck, Sanket J Mishra, Matthew M Champion, Brian S J Blagg","doi":"10.1016/j.mcpro.2025.101043","DOIUrl":null,"url":null,"abstract":"<p><p>Hsp90 (90 kDa heat shock protein) is a central molecular chaperone responsible for the folding and activation of >400 client proteins, causing it to be a highly sought after drug target for the treatment of cancer. Hsp90 pan-inhibitors have been evaluated in the clinic, but on- and off-target toxicities have limited their development. The emergence of Hsp90β-selective inhibitors has been proposed as a safer therapeutic alternative. However, since they in theory only target a portion of the Hsp90-regulated proteome, a deeper understanding of their mechanism of action and whether they exhibit selectivity for cancer over normal cells has remained uninvestigated. Herein, we show that Hsp90β-selective inhibitors, NDNB1 and NDNB1182, exhibit a moderate selectivity for triple-negative breast cancer (TNBC) over normalized MCF-10A cells in contrast to pan-inhibitors, which do not exhibit a selectivity. This article contains the first proteomic analysis of Hsp90β-selective inhibitors. We have employed a traditional bottom-up LC-MS/MS proteomics approach to explore the potential mechanisms of action underlying the anticancer effects of NDNB1 and NDNB1182 against TNBC. Primarily, inhibition of kinases and associated cell signaling pathways, cell cycle proteins, and DNA repair were notable processes affected by Hsp90β inhibition, to name a few. Further investigation of the impact on Hsp90β interactors allowed a fuller understanding of Hsp90β-dependent processes. We also identified RAD9A, cyclin-dependent kinase 1 (CDK1), and ribosomal protein S9 (RPS9) as potential Hsp90β client substrates. The three example proteins selected exemplify a mechanistic explanation for inhibition of DNA repair (RAD9A), cell cycle (CDK1), and translation (RPS9), shedding some light on some of the implications of Hsp90β inhibition as it pertains to TNBC. Therefore, previously unknown clients, Hsp90β interactors, or Hsp90β-regulated proteins could be determined using the results from this study.</p>","PeriodicalId":18712,"journal":{"name":"Molecular & Cellular Proteomics","volume":" ","pages":"101043"},"PeriodicalIF":5.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446539/pdf/","citationCount":"0","resultStr":"{\"title\":\"Proteomic Analysis of Hsp90β-Selective Inhibitors Against Triple-Negative Breast Cancer to Gain a Mechanistic Insight.\",\"authors\":\"Tyelor S Reynolds, Daniel D Hu, Simon D Weaver, Emma C Ronck, Sanket J Mishra, Matthew M Champion, Brian S J Blagg\",\"doi\":\"10.1016/j.mcpro.2025.101043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hsp90 (90 kDa heat shock protein) is a central molecular chaperone responsible for the folding and activation of >400 client proteins, causing it to be a highly sought after drug target for the treatment of cancer. Hsp90 pan-inhibitors have been evaluated in the clinic, but on- and off-target toxicities have limited their development. The emergence of Hsp90β-selective inhibitors has been proposed as a safer therapeutic alternative. However, since they in theory only target a portion of the Hsp90-regulated proteome, a deeper understanding of their mechanism of action and whether they exhibit selectivity for cancer over normal cells has remained uninvestigated. Herein, we show that Hsp90β-selective inhibitors, NDNB1 and NDNB1182, exhibit a moderate selectivity for triple-negative breast cancer (TNBC) over normalized MCF-10A cells in contrast to pan-inhibitors, which do not exhibit a selectivity. This article contains the first proteomic analysis of Hsp90β-selective inhibitors. We have employed a traditional bottom-up LC-MS/MS proteomics approach to explore the potential mechanisms of action underlying the anticancer effects of NDNB1 and NDNB1182 against TNBC. Primarily, inhibition of kinases and associated cell signaling pathways, cell cycle proteins, and DNA repair were notable processes affected by Hsp90β inhibition, to name a few. Further investigation of the impact on Hsp90β interactors allowed a fuller understanding of Hsp90β-dependent processes. We also identified RAD9A, cyclin-dependent kinase 1 (CDK1), and ribosomal protein S9 (RPS9) as potential Hsp90β client substrates. The three example proteins selected exemplify a mechanistic explanation for inhibition of DNA repair (RAD9A), cell cycle (CDK1), and translation (RPS9), shedding some light on some of the implications of Hsp90β inhibition as it pertains to TNBC. Therefore, previously unknown clients, Hsp90β interactors, or Hsp90β-regulated proteins could be determined using the results from this study.</p>\",\"PeriodicalId\":18712,\"journal\":{\"name\":\"Molecular & Cellular Proteomics\",\"volume\":\" \",\"pages\":\"101043\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446539/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular & Cellular Proteomics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.mcpro.2025.101043\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular & Cellular Proteomics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.mcpro.2025.101043","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

摘要

Hsp90是负责bbbb400客户蛋白折叠和激活的中心分子伴侣,使其成为癌症治疗中备受追捧的药物靶点。Hsp90泛抑制剂已经在临床中进行了评估,但靶标和脱靶毒性限制了它们的发展。hsp90 β选择性抑制剂的出现被认为是一种更安全的治疗选择。然而,由于理论上它们只针对一部分hsp90调节的蛋白质组,因此对它们的作用机制以及它们是否比正常细胞表现出对癌症的选择性的更深入的了解仍未得到研究。在这里,我们发现hsp90 β选择性抑制剂NDNB1和NDNB1182对规范化MCF-10A细胞的TNBC表现出中等的选择性,而泛抑制剂则不表现出选择性。这篇论文包含了hsp90 β选择性抑制剂的第一个蛋白质组学分析。我们采用传统的自下而上LC-MS/MS蛋白质组学方法来探索NDNB1和NDNB1182对三阴性乳腺癌(TNBC)的抗癌作用的潜在作用机制。首先,激酶和相关细胞信号通路、细胞周期蛋白和DNA修复的抑制是受Hsp90β抑制影响的显著过程,仅举几例。进一步研究对Hsp90β相互作用物的影响,可以更全面地了解Hsp90β依赖过程。我们还发现RAD9A、CDK1和RPS9是潜在的Hsp90β客户底物。所选择的三个示例蛋白举例说明了dna修复(RAD9A),细胞周期(CDK1)和翻译(RPS9)抑制的机制解释,揭示了与TNBC相关的Hsp90β抑制的一些含义。因此,可以利用本研究的结果确定以前未知的宿主、Hsp90β相互作用物或Hsp90β调节蛋白。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Proteomic Analysis of Hsp90β-Selective Inhibitors Against Triple-Negative Breast Cancer to Gain a Mechanistic Insight.

Hsp90 (90 kDa heat shock protein) is a central molecular chaperone responsible for the folding and activation of >400 client proteins, causing it to be a highly sought after drug target for the treatment of cancer. Hsp90 pan-inhibitors have been evaluated in the clinic, but on- and off-target toxicities have limited their development. The emergence of Hsp90β-selective inhibitors has been proposed as a safer therapeutic alternative. However, since they in theory only target a portion of the Hsp90-regulated proteome, a deeper understanding of their mechanism of action and whether they exhibit selectivity for cancer over normal cells has remained uninvestigated. Herein, we show that Hsp90β-selective inhibitors, NDNB1 and NDNB1182, exhibit a moderate selectivity for triple-negative breast cancer (TNBC) over normalized MCF-10A cells in contrast to pan-inhibitors, which do not exhibit a selectivity. This article contains the first proteomic analysis of Hsp90β-selective inhibitors. We have employed a traditional bottom-up LC-MS/MS proteomics approach to explore the potential mechanisms of action underlying the anticancer effects of NDNB1 and NDNB1182 against TNBC. Primarily, inhibition of kinases and associated cell signaling pathways, cell cycle proteins, and DNA repair were notable processes affected by Hsp90β inhibition, to name a few. Further investigation of the impact on Hsp90β interactors allowed a fuller understanding of Hsp90β-dependent processes. We also identified RAD9A, cyclin-dependent kinase 1 (CDK1), and ribosomal protein S9 (RPS9) as potential Hsp90β client substrates. The three example proteins selected exemplify a mechanistic explanation for inhibition of DNA repair (RAD9A), cell cycle (CDK1), and translation (RPS9), shedding some light on some of the implications of Hsp90β inhibition as it pertains to TNBC. Therefore, previously unknown clients, Hsp90β interactors, or Hsp90β-regulated proteins could be determined using the results from this study.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Molecular & Cellular Proteomics
Molecular & Cellular Proteomics 生物-生化研究方法
CiteScore
11.50
自引率
4.30%
发文量
131
审稿时长
84 days
期刊介绍: The mission of MCP is to foster the development and applications of proteomics in both basic and translational research. MCP will publish manuscripts that report significant new biological or clinical discoveries underpinned by proteomic observations across all kingdoms of life. Manuscripts must define the biological roles played by the proteins investigated or their mechanisms of action. The journal also emphasizes articles that describe innovative new computational methods and technological advancements that will enable future discoveries. Manuscripts describing such approaches do not have to include a solution to a biological problem, but must demonstrate that the technology works as described, is reproducible and is appropriate to uncover yet unknown protein/proteome function or properties using relevant model systems or publicly available data. Scope: -Fundamental studies in biology, including integrative "omics" studies, that provide mechanistic insights -Novel experimental and computational technologies -Proteogenomic data integration and analysis that enable greater understanding of physiology and disease processes -Pathway and network analyses of signaling that focus on the roles of post-translational modifications -Studies of proteome dynamics and quality controls, and their roles in disease -Studies of evolutionary processes effecting proteome dynamics, quality and regulation -Chemical proteomics, including mechanisms of drug action -Proteomics of the immune system and antigen presentation/recognition -Microbiome proteomics, host-microbe and host-pathogen interactions, and their roles in health and disease -Clinical and translational studies of human diseases -Metabolomics to understand functional connections between genes, proteins and phenotypes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信